The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL12 2022 | Recent updates in HL research & the importance of improving treatment for elderly & frail patients
Ninja Övergaard, PhD, Uppsala University, Uppsala, Sweden, briefly comments on recent developments in Hodgkin lymphoma (HL) research, highlighting that a growing number of studies are investigating HL in elderly and frail patients, and that promising novel agents are being explored. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
